Generation of a highly specific monoclonal anti-infliximab antibody for harmonization of TNF-coated infliximab assays

Determination of infliximab (IFX) serum concentrations has been used for treatment optimization of patients with inflammatory bowel disease (IBD). A wide range of ELISA assays exists to quantitate IFX. Most of these assays lack specificity and cross-react with other anti-tumor necrosis factor (TNF) agents. The ability of these IFX assays to detect IFX in complex with anti-drug antibodies is not known. The objective of our study was to develop an IFX-specific immunoassay to monitor IFX serum concentrations and to evaluate the impact of anti-drug antibodies on the assay performance.

Publication year:2015

BOF-keylabel:yes

IOF-keylabel:yes

BOF-publication weight:1

CSS-citation score:2

Authors from:Higher Education

Accessibility:Closed